Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00783341 · ClinicalTrials.gov registry record · Phase 1
Study of the Safety, Tolerability, and Pharmacokinetics of GAP-134 Administered Intravenously
A Phase 1 study, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
NCT00783341: Completed Phase 1 study, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
NCT00783341 is a Phase 1 study that has completed, run by Wyeth is now a wholly owned subsidiary of Pfizer. The registered enrollment target is 25 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (58% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00783341, a Phase 1 study, has completed, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
Study Summary
This study will evaluate the safety, tolerability, and pharmacokinetics (PK) of ascending doses of GAP 134 administered as 6-day continuous IV infusions to healthy subjects.
Interventions
- DRUG placebo
- DRUG GAP-134
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2008-11 |
| Est. Completion | 2009-02 |
| Phase | Phase 1 |
What the finished NCT00783341 record still lists
NCT00783341 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (58% lower).
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00783341 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00783341 about?
NCT00783341 is a clinical study titled "Study of the Safety, Tolerability, and Pharmacokinetics of GAP-134 Administered Intravenously". This study will evaluate the safety, tolerability, and pharmacokinetics (PK) of ascending doses of GAP 134 administered as 6-day continuous IV infusions to healthy subjects.
What is the current status of trial NCT00783341?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2008-11. Estimated completion is 2009-02.
What interventions are being tested in trial NCT00783341?
The interventions under investigation include: placebo (DRUG), GAP-134 (DRUG).
Who is sponsoring clinical trial NCT00783341?
This trial is sponsored by Wyeth is now a wholly owned subsidiary of Pfizer, which has 167 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00783341's enrollment target sits among peer trials
25 1495th of 2000 higher than 481 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia